Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Clinical IVb Stage Oral Squamous Cell Carcinomas Patients”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Early research (Phase 1)Study completedNCT01334177
What this trial is testing

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland Cancer+38 more
University of Washington 13
Large-scale testing (Phase 3)Looking for participantsNCT07441681
What this trial is testing

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Who this might be right for
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+13 more
NRG Oncology
Testing effectiveness (Phase 2)Study completedNCT04541355
What this trial is testing

Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin

Who this might be right for
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Advanced Head and Neck Squamous Cell Carcinoma+26 more
Hyunseok Kang, MD
Early research (Phase 1)Active Not RecruitingNCT04533750
What this trial is testing

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Who this might be right for
Advanced Head and Neck Squamous Cell CarcinomaAdvanced Hypopharyngeal Squamous Cell CarcinomaAdvanced Laryngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI) 21
Testing effectiveness (Phase 2)Looking for participantsNCT06532279
What this trial is testing

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Who this might be right for
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+38 more
NRG Oncology
Not applicableStudy completedNCT02245100
What this trial is testing

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaSalivary Gland Squamous Cell CarcinomaStage IIIA Non-small Cell Lung Cancer+27 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 130
Testing effectiveness (Phase 2)Active Not RecruitingNCT04862650
What this trial is testing

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell Carcinoma+22 more
Marcelo Bonomi
Early research (Phase 1)Study completedNCT02035527
What this trial is testing

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland Cancer+34 more
Ohio State University Comprehensive Cancer Center 3
Large-scale testing (Phase 3)Study completedNCT03258554
What this trial is testing

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Who this might be right for
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Head and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI) 196
Testing effectiveness (Phase 2)Looking for participantsNCT06277791
What this trial is testing

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma

Who this might be right for
Clinical IVb Stage Oral Squamous Cell Carcinomas Patients
Hospital of Stomatology, Wuhan University 35
Testing effectiveness (Phase 2)Looking for participantsNCT07195734
What this trial is testing

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Who this might be right for
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)
454
16
98
46
180